Stoke Therapeutics, Inc. STOK Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32.08M-83.2% | $184.42M+405% | $205.63M+1,128% | $199.89M+1,219% | $190.91M+2,333% | ||
| $144.92M+45.7% | $137.92M+54.7% | $119.65M+36.8% | $104.16M+21.7% | $99.44M+17.0% | ||
| $72.41M— | $67.09M— | $58.79M— | $55.45M— | —— | ||
| $217.33M+42.4% | $205.01M+48.6% | $178.44M+33.1% | $159.61M+23.1% | $152.67M+20.9% | ||
| -$185.25M-584% | -$20.59M+79.7% | $27.2M+123% | $40.28M+135% | $38.24M+132% | ||
| -577.5%-597pp | -11.2%+266pp | 13.2%+714pp | 20.2%+776pp | 20%+1,530pp | ||
| $14.26M+8.9% | $13.76M+8.9% | $13.11M+7.0% | $13.19M+16.1% | $13.1M+28.0% | ||
| $14.2M+6.7% | $13.71M+10.6% | $13.37M+12.9% | $13.48M+22.9% | $13.31M+34.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$169.77M-438% | -$6.89M+92.3% | $40.57M+138% | $52.48M+151% | $50.27M+146% | ||
| -529.2%-556pp | -3.7%+240pp | 19.7%+650pp | 26.3%+710pp | 26.3%+1,410pp | ||
| -$2.81-451% | -$0.12+92.8% | $0.68+132% | $0.86+139% | $0.80+133% | ||
| -$183.52M-555% | -$18.82M+81.0% | $29.09M+125% | $42.27M+138% | $40.33M+135% | ||
| -572.1%-593pp | -10.2%+261pp | 14.1%+701pp | 21.1%+761pp | 21.1%+1,500pp | ||
| -$185.25M-584% | -$20.59M+79.7% | $27.2M+123% | $40.28M+135% | $38.24M+132% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Stoke Therapeutics, Inc.'s revenue?
- Stoke Therapeutics, Inc. (STOK) generated $32.1M in revenue over the trailing twelve months, down 83.2% year over year.
- Is Stoke Therapeutics, Inc. profitable?
- Stoke Therapeutics, Inc. is not currently profitable: it reported a net loss of $169.8M over the trailing twelve months, a -529.2% net margin.
- What is Stoke Therapeutics, Inc.'s earnings per share?
- Stoke Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.81.
- Where does Stoke Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
